Summary

Overview
The global hemostatic matrix market reached US$ 2.92 billion in 2023 and is expected to reach US$ 4.70 billion by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.
A hemostatic matrix is a specialized medical product designed to control bleeding during surgical procedures. It typically consists of a flowable gelatin matrix combined with a thrombin component. This combination is particularly useful in situations where traditional surgical techniques, such as cautery, ligature, or sutures, are either, impractical or ineffective.
The rising number of surgical are expected to drive the demand for the hemostatic matrix market. For instance, according to the World Health Organization (WHO) data in December 2023, over, 1,19 million people die in road accidents annually, many suffering from severe bleeding that requires surgical intervention. A need for effective hemostatic matrix agents in trauma surgeries.
Market Dynamics: Drivers
Growing number of surgical procedures
The demand for the global hemostatic matrix market is driven by multiple factors. The rise in surgical procedures worldwide is a primary driver for the hemostatic matrix market. As the global population ages, there is a higher incidence of age-related health issues that require surgical procedures. As per University of Virginia news in July 2024, by 2030, it is projected that 20% of the U.S. population will be over 65 years old, leading to increased demand for surgeries such as joint replacements and cardiovascular procedures. The rising demand for surgical procedures contributes to the hemostatic matrix market's expansion.
Furthermore, key players in the industry product launches and approvals that would drive this hemostatic matrix market growth. For instance, in April 2023, Olympus launched the EndoClot portfolio, which includes hemostatic agents and a submucosal injection solution, specifically designed for gastrointestinal procedures. This innovative product line aims to enhance hemostasis and facilitate lifting during endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR). This solution is intended to provide a long-lasting mucosal lift during endoscopic procedures.
Thus, the growing number of surgical procedures is expected to drive the hemostatic matrix market growth.
Restraints
Product recalls
Product recalls represent a significant restraint in the global hemostatic matrix market, impacting manufacturers, healthcare providers, and patients. Recalls often arise due to safety concerns that could compromise patient health. For instance, if a hemostatic agent is found to be ineffective or contaminated, it could lead to adverse surgical outcomes.
For instance, in September 2024, Baxter Healthcare issued a voluntary recall for certain batches of its Tisseel Lyo Fibrin Sealant Kits due to issues identified during stability studies. This recall is significant as it highlights the importance of product quality and safety in medical devices, particularly those used in surgical settings. Thus, the above factors could hinder the hemostatic matrix market.
Segment Analysis
The global hemostatic matrix market is segmented based on product type, form, application, end-user, distribution channel, and region.
The thrombin-based hemostatic matrix segment accounted for approximately XX% of the global hemostatic matrix market share
The thrombin-based hemostatic matrix segment is expected to hold the largest market share over the forecast period. A thrombin-based hemostatic matrix is a medical device utilized primarily to control bleeding during surgical procedures. It combines a gelatin matrix with thrombin, creating a product that enhances hemostasis when traditional methods, such as ligatures, are ineffective or impractical. The thrombin-based hemostatic matrix operates through two primary mechanisms: mechanical action and biochemical action. These mechanisms work synergistically to control bleeding during surgical procedures, making these matrices effective in a variety of clinical settings.
Furthermore, key players in the industry more focus on the research activities and product developments that would drive this segment's growth in the hemostatic matrix market. According to NCBI research study data in October 2023, the effectiveness of Floseal, a thrombin-based hemostatic matrix, in minimizing blood loss and reducing transfusion requirements during total knee arthroplasty (TKA) remains a contentious issue within the medical community. This meta-analysis aims to synthesize the findings from recent randomized controlled trials (RCTs) to evaluate the efficacy and safety of Floseal specifically in the context of TKA. These factors have solidified the segment's position in the hemostatic matrix market.
Geographical Analysis
North America accounted for approximately XX% of the global hemostatic matrix market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases such as cardiovascular disease (CVD), diabetes, and obesity. These conditions often required surgical treatments, contributing to the growing volume of surgeries performed.
As the prevalence of CVD rises, there will be a corresponding increase in surgical interventions related to cardiovascular conditions, such as coronary artery bypass grafting (CABG), valve replacements, and other cardiac surgeries. The rising number of surgeries is a primary driver for the hemostatic matrix market. As per the American Heart Association news in July 2024, with more than 184 million people expected to be affected by some form of CVD by 2050, and total CVD-related costs anticipated to triple to approximately $1.8 trillion, the demand for effective hemostatic matrix solutions.
Furthermore, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, investments, and product launches & approvals would propel the hemostatic matrix market growth. For instance, in November 2023, in New Jersey, Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIA, an innovative hemostatic sealing patch designed to address challenging bleeding situations during surgical procedures. This product is notable for its unique synthetic polymer technology, which allows it to be effective on both sides, making it the first of its kind in the market. The patch is engineered for maximum adaptability; it can be stuffed, rolled, pulled apart, trimmed, and tailored, facilitating its use in both open and minimally invasive surgeries.
In clinical trials, ETHIZIA demonstrated the ability to stop bleeding in 80% of patients within just 30 seconds, significantly faster than traditional fibrin sealant patches. Thus, the above factors are consolidating the region's position as a dominant force in the hemostatic matrix market.
Market Segmentation
By Product Type
• Gelatin-based Hemostatic Matrix
• Collagen-based Hemostatic Matrix
• Thrombin-based Hemostatic Matrix
• Combination Hemostatic Matrix
By Form
• Gel
• Foam
• Powder
• Paste
By Application
• Surgical Procedures
o Cardiovascular Surgery
o Orthopedic Surgery
o Neurosurgery
o General Surgery
o Gynecological Surgery
o Urology Surgery
o Others
• Trauma Care
• Wound Care
By End-User
• Hospitals
• Ambulatory Surgical Centers
• Trauma Centers
• Specialty Clinics
By Distribution Channel
• Direct Sales
• Medical Supply Distributors
• Online Sales
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the hemostatic matrix market include Pfizer Inc., Ethicon (Johnson & Johnson), Baxter International Inc., Becton, Dickinson and Company (BD), B. Braun SE, Integra LifeSciences Corporation., CryoLife, Inc. (Artivion, Inc), Advanced Medical Solutions Group plc, Aegis Lifesciences, and Teleflex Incorporated. among others.
Key Developments
 In August 2023, Teleflex Incorporated received clearance from the U.S. Food and Drug Administration (FDA) for its QuikClot Control+ Hemostatic Device, expanding its indications to include the management of mild and moderate bleeding in cardiac surgical procedures, as well as bone surface bleeding following a sternotomy. This development allows clinicians to utilize the QuikClot Control+ device for comprehensive bleeding control in cardiac surgeries.
 In July 2023, Baxter International Inc. launched PERCLOT Absorbable Hemostatic Powder in the U.S., marking a significant addition to its portfolio of surgical innovations. PERCLOT is designed as a passive, absorbable hemostatic agent specifically for patients with intact coagulation systems, aimed at managing mild bleeding during surgical procedures.
 In March 2023, Axio Biosolutions, a med-tech company based in Bengaluru, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ax-Surgi Surgical Hemostat. This marks a significant milestone as Ax-Surgi becomes the first chitosan-based hemostatic agent approved for controlling severe surgical bleeding.
 In September 2022, Medtronic received U.S. Food and Drug Administration (FDA) clearance for its Nexpowder Endoscopic Hemostasis System, a significant advancement in the management of upper gastrointestinal (GI) bleeding. This system is specifically designed to treat nonvariceal upper GI bleeding, which accounts for a substantial portion of acute GI bleeding cases.
 In May 2022, Ethicon, a subsidiary of Johnson & Johnson MedTech, acquired GATT Technologies B.V., a Netherlands-based company specializing in synthetic polymers for hemostatic and sealant products. This acquisition is significant as it enhances Ethicon's capabilities to develop innovative solutions for complex surgical bleeding and leakage challenges.
Why Purchase the Report?
• To visualize the global hemostatic matrix market segmentation based on product type, form, application, end-user, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the hemostatic matrix market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global hemostatic matrix market report would provide approximately 78 tables, 75 figures, and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Form
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Distribution Channels
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Number of Surgical Procedures
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Product Recalls
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Gelatin-based Hemostatic Matrix *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Collagen-based Hemostatic Matrix
6.4. Thrombin-based Hemostatic Matrix
6.5. Combination Hemostatic Matrix
7. By Form
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
7.1.2. Market Attractiveness Index, By Form
7.2. Gel *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Foam
7.4. Powder
7.5. Paste
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Surgical Procedures *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Cardiovascular Surgery
8.2.4. Orthopedic Surgery
8.2.5. Neurosurgery
8.2.6. General Surgery
8.2.7. Gynecological Surgery
8.2.8. Urology Surgery
8.2.9. Others
8.3. Trauma Care
8.4. Wound Care
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Trauma Centers
9.5. Specialty Clinics
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Direct Sales *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Medical Supply Distributors
10.4. Online Sales
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ethicon (Johnson & Johnson)
13.3. Baxter International Inc.
13.4. Becton, Dickinson and Company (BD)
13.5. B. Braun SE
13.6. Integra LifeSciences Corporation.
13.7. CryoLife, Inc. (Artivion, Inc)
13.8. Advanced Medical Solutions Group plc
13.9. Aegis Lifesciences
13.10. Teleflex Incorporated.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us